UK biotech RQ Bio is partnering with AstraZeneca as it races to keep its antibody to protect immunocompromised patients from Covid-19 up to date with the latest variants. The Anglo-Swedish pharmaceutical company recently launched a trial of a second generation of its Evusheld antibody, as the original appears unable to prevent infection from the XBB 1.5 variant. The antibodies are used to protect people who do not respond to vaccines, for example, if they have certain cancers.
Astrazeneca (AZN) closed the most recent trading day at $65.53, moving -0.7% from the previous trading session.
As far as life goals go, defeating cancer might be deemed one of the more fanciful.